535 related articles for article (PubMed ID: 14655910)
21. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder.
Sangal RB; Blumer JL; Lankford DA; Grinnell TA; Huang H
Pediatrics; 2014 Oct; 134(4):e1095-103. PubMed ID: 25266438
[TBL] [Abstract][Full Text] [Related]
22. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study.
Scharf MB; Black J; Hull S; Landin R; Farber R
Sleep; 2007 Jun; 30(6):743-52. PubMed ID: 17580596
[TBL] [Abstract][Full Text] [Related]
23. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.
Pollack MH; Hoge EA; Worthington JJ; Moshier SJ; Wechsler RS; Brandes M; Simon NM
J Clin Psychiatry; 2011 Jul; 72(7):892-7. PubMed ID: 21367352
[TBL] [Abstract][Full Text] [Related]
24. Eszopiclone for insomnia.
Rösner S; Englbrecht C; Wehrle R; Hajak G; Soyka M
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010703. PubMed ID: 30303519
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
Krystal A; Fava M; Rubens R; Wessel T; Caron J; Wilson P; Roth T; McCall WV
J Clin Sleep Med; 2007 Feb; 3(1):48-55. PubMed ID: 17557453
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model.
Botteman MF; Ozminkowski RJ; Wang S; Pashos CL; Schaefer K; Foley DJ
CNS Drugs; 2007; 21(4):319-34. PubMed ID: 17381185
[TBL] [Abstract][Full Text] [Related]
28. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone.
Boyle J; Trick L; Johnsen S; Roach J; Rubens R
Hum Psychopharmacol; 2008 Jul; 23(5):385-97. PubMed ID: 18350566
[TBL] [Abstract][Full Text] [Related]
29. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
Roth T; Krystal A; Steinberg FJ; Singh NN; Moline M
Sleep; 2013 Feb; 36(2):189-96. PubMed ID: 23372266
[TBL] [Abstract][Full Text] [Related]
30. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
[TBL] [Abstract][Full Text] [Related]
31. Eszopiclone versus zopiclone in the treatment of insomnia.
Pinto LR; Bittencourt LR; Treptow EC; Braga LR; Tufik S
Clinics (Sao Paulo); 2016 Jan; 71(1):5-9. PubMed ID: 26872077
[TBL] [Abstract][Full Text] [Related]
32. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg.
Krystal AD; Huang H; Zummo J; Grinnell T; Marshall RD
Sleep Med; 2012 Jun; 13(6):691-6. PubMed ID: 22465450
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
Krystal AD; Durrence HH; Scharf M; Jochelson P; Rogowski R; Ludington E; Roth T
Sleep; 2010 Nov; 33(11):1553-61. PubMed ID: 21102997
[TBL] [Abstract][Full Text] [Related]
34. Patient Background Factors Affecting the Therapeutic Outcomes in Response to Eszopiclone in Adult Patients with Chronic Insomnia: A Post Hoc Analysis of a Double-Blind Phase III Study in Japan.
Inoue Y; Kamijo A; Nagai R
J Clin Sleep Med; 2015 Oct; 11(10):1171-8. PubMed ID: 26094929
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.
Krystal AD; Lankford A; Durrence HH; Ludington E; Jochelson P; Rogowski R; Roth T
Sleep; 2011 Oct; 34(10):1433-42. PubMed ID: 21966075
[TBL] [Abstract][Full Text] [Related]
36. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial.
Joffe H; Petrillo L; Viguera A; Koukopoulos A; Silver-Heilman K; Farrell A; Yu G; Silver M; Cohen LS
Am J Obstet Gynecol; 2010 Feb; 202(2):171.e1-171.e11. PubMed ID: 20035910
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial.
Lydiard RB; Lankford DA; Seiden DJ; Landin R; Farber R; Walsh JK
J Clin Sleep Med; 2006 Jul; 2(3):309-15. PubMed ID: 17561543
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration.
Huedo-Medina TB; Kirsch I; Middlemass J; Klonizakis M; Siriwardena AN
BMJ; 2012 Dec; 345():e8343. PubMed ID: 23248080
[TBL] [Abstract][Full Text] [Related]
40. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness.
Walsh JK; Salkeld L; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2010 Jan; 11(1):23-30. PubMed ID: 19945340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
